S100P and hepatocellular carcinoma: Further analysis showed that the majority of HCC cases with the β-catenin mutation had low tumor stage and a lower incidence of ETR, regardless of the presence or absence of S100P expression (7 of 13 versus 15 of 19 and 2 of 9 versus 2 of 17, respectively, both P>0.05).